Literature DB >> 8660583

High-performance liquid chromatographic determination of anandamide amidase activity in rat brain microsomes.

W Lang1, C Qin, W A Hill, S Lin, A D Khanolkar, A Makriyannis.   

Abstract

A rapid, sensitive, and reliable method for measuring anandamide amidase activity in rat brain microsomes by reversed-phase high-performance liquid chromatography (RP-HPLC) and its applications are described. Enzymatic activity was assayed by the determination of the rates of hydrolysis of anandamide or its analogs at 37 degrees C. The reaction products were separated using an ODS guard column eluted with aqueous phosphoric acid-acetonitrile and quantitated with uv detection at 204 nm and an external standard method. Baseline separation of the acid products from their substrates was completed in less than 2 min. The detection limits were 1.4 pmol for arachidonic acid and 0.22 pmol for anandamide at a signal to noise ratio of 4:1. The stability of anandamide in the acidic mobile phase was tested, and no significant decomposition was observed up to 1 h. The method was successfully applied to the examination of substrate specificity as well as for testing the ability of amidase inhibitors to block its hydrolysis. Kinetic constants obtained for (S)-methanandamide were an apparent Km of 8.6 +/- 1.3 microM and a Vmax of 362 +/- 16 pmol/min/mg of protein. A highly potent inhibitor, palmitylsulfonyl fluoride (PSF), was found to have an IC50 of 50 nM. PSF is 210 times as potent as phenylmethylsulfonyl fluoride. The method offers several advantages over existing methodology using radioisotopes or a solvent extraction procedure.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8660583     DOI: 10.1006/abio.1996.0247

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  8 in total

1.  2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective.

Authors:  Alexandros Makriyannis
Journal:  J Med Chem       Date:  2014-05-01       Impact factor: 7.446

2.  Full mass spectrometric characterization of human monoacylglycerol lipase generated by large-scale expression and single-step purification.

Authors:  Nikolai Zvonok; John Williams; Meghan Johnston; Lakshmipathi Pandarinathan; David R Janero; Jing Li; Srinivasan C Krishnan; Alexandros Makriyannis
Journal:  J Proteome Res       Date:  2008-05-02       Impact factor: 4.466

3.  A novel monoacylglycerol lipase inhibitor with analgesic and anti-inflammatory activity.

Authors:  Victoria Magrioti; George Naxakis; Dimitra Hadjipavlou-Litina; Alexandros Makriyannis; George Kokotos
Journal:  Bioorg Med Chem Lett       Date:  2008-09-12       Impact factor: 2.823

4.  Conformationally constrained analogues of 2-arachidonoylglycerol.

Authors:  Subramanian K Vadivel; Sundararaman Vardarajan; Richard I Duclos; JodiAnne T Wood; Jianxin Guo; Alexandros Makriyannis
Journal:  Bioorg Med Chem Lett       Date:  2007-08-21       Impact factor: 2.823

Review 5.  Cannabinoids and multiple sclerosis.

Authors:  Roger G Pertwee
Journal:  Mol Neurobiol       Date:  2007-06-26       Impact factor: 5.590

6.  The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action.

Authors:  D M Kerr; B Harhen; B N Okine; L J Egan; D P Finn; M Roche
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

7.  Endocannabinoid enzyme engineering: soluble human thio-monoacylglycerol lipase (sol-S-hMGL).

Authors:  Ioannis Karageorgos; Nikolai Zvonok; David R Janero; V Kiran Vemuri; Vidyanand Shukla; Thomas E Wales; John R Engen; Alexandros Makriyannis
Journal:  ACS Chem Neurosci       Date:  2012-03-20       Impact factor: 4.418

8.  Development of novel tail-modified anandamide analogs.

Authors:  Fenmei Yao; Chen Li; Subramanian K Vadivel; Anna L Bowman; Alexandros Makriyannis
Journal:  Bioorg Med Chem Lett       Date:  2008-07-31       Impact factor: 2.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.